Locations:

How Autoimmune Disorders Impact Myocardial Infarction Treatment and Long-Term Outcomes

Largest study to date finds lower intervention rates, elevated long-term mortality

Knowing the signs can save your life

Among patients hospitalized for myocardial infarction (MI), the presence of a rheumatic immune-mediated inflammatory disease (IMID) was associated with reduced use of coronary interventions and significantly increased risks of all-cause mortality and adverse cardiovascular outcomes in the next two years, finds a large Medicare database analysis published in Journal of the American Heart Association (2022;11:e026411).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Autoimmune disorders are associated with myriad cardiovascular manifestations and an elevated risk of premature coronary artery disease,” says Cleveland Clinic cardiologist Amgad Mentias, MD, MSc, the study’s corresponding author. “Nevertheless, studies of post-MI outcomes in patients with autoimmune disorders have been limited in size and yielded inconsistent results. We conducted our analysis, the largest and most contemporary study of this population to date, to better understand how the presence of autoimmune disorders affects MI treatment and long-term outcomes.”

Assessing autoimmune disease prevalence among MI patients

Using the nationwide Medicare Provider Analysis and Review (MedPAR) database, Dr. Mentias and Cleveland Clinic colleagues identified 1.65 million Medicare beneficiaries hospitalized with an MI diagnosis from 2014 to 2019. They then identified those who had a concomitant rheumatic IMID, who totaled 60,072, or 3.6% of the cohort. The IMIDs consisted of the following:

  • Rheumatoid arthritis (n = 46,747)
  • Systemic lupus erythematosus (n = 7,362)
  • Psoriasis (n = 3,098)
  • Systemic sclerosis (n = 1,738)
  • Myositis/dermatomyositis (n = 1,127)

Compared with the rest of the cohort, those with a rheumatic IMID were slightly but significantly younger, more likely to be women (66.9% vs. 44.2%) and more likely to present with non-ST-elevation MI (non-STEMI) than with STEMI. Additionally, rates of coronary angiography, percutaneous coronary intervention and coronary artery bypass grafting were all significantly lower in patients with versus without a rheumatic IMID, regardless of MI type (non-STEMI or STEMI).

Advertisement

MI outcomes with and without autoimmune disease

To assess clinical outcomes, the researchers applied a 1:3 propensity-score matching scheme to match cohort patients with a rheumatic IMID (n = 59,820) with cohort patients without a rheumatic IMID (n = 178,547). By design, the arms were identically matched for age, sex, race, and prevalence of non-STEMI versus STEMI, with comorbidities and other variables well balanced between the groups.

Over median follow-up of 24 months (interquartile range, 9-45 months), the study’s primary outcome of all-cause mortality was significantly higher in MI patients with versus without a rheumatic IMID (hazard ratio [HR] = 1.15 [1.14-1.17]; P < 0.001). The presence of a rheumatic IMID conferred significant increases in a number of secondary outcomes as well, including:

  • Heart failure (12% relative increase; P < 0.001)
  • Recurrent MI (8% relative increase; P < 0.001)
  • Need for coronary reintervention (6% relative increase; P = 0.04)

These elevated risks with rheumatic IMIDs remained statistically significant after sensitivity analysis using multivariable Cox regression analysis.

Clinical takeaways for a challenging population

“This study yielded several notable findings,” says Dr. Mentias. “First, underlying rheumatic autoimmune disease was associated with a 15% relative rise in the risk of all-cause mortality by one year after MI and continuing throughout follow-up. Second, it was also associated with poorer outcomes in multiple other cardiovascular endpoints. Finally, MI patients with rheumatic autoimmune disease were predominantly female and were less likely to undergo coronary angiography or revascularization for their MI.”

Advertisement

The latter finding is provocative, the authors note. “It is possible that, despite the propensity matching, the patients with autoimmune disease were clinically more ill or had coronary anatomy that was less suited to revascularization,” says Cleveland Clinic cardiologist and study co-author Khaled Ziada, MD. “Unfortunately, the database did not contain information specific to coronary anatomy. However, autoimmune disease per se does not preclude revascularization when that is considered to be feasible and safe.”

“This study’s findings reinforce our recommendation that patients with concurrent autoimmune disease and cardiovascular disease be managed by a cardio-rheumatologist in conjunction with a rheumatologist,” adds co-author Heba Wassif, MD, MPH, Director of Cleveland Clinic’s Center for Cardio-Rheumatology and Immunology. “Such providers are well equipped to offer what these patients often need when presenting with MI — namely, coronary intervention, aggressive risk factor optimization and medical therapy intensification to attenuate their increased cardiovascular risk.”

Advertisement

Related Articles

axial image of the human chest showing the heart and other organs

How Imaging Can Guide Smarter Aortic Valve and Root Decisions

New review proposes a multimodality framework for matching patients to procedures

color cardiac echo next to model of a bulging aorta

Distinctive CME on Valve Imaging and Connective Tissue Disorders on Tap for March 2027

In-depth live symposia in Florida and Cleveland feature interdisciplinary experts from around the nation

yellow and red illustration of blood cells moving through a blood vessel

First-in-Human Data Show One siRNA Can Lower Both LDL-C and Triglycerides

Early results for ARO-DIMER-PA point to a more streamlined way to treat mixed hyperlipidemia

blood vessel on top of a DNA double helix

CRISPR-Cas9 Gene Editing Therapy Safely Slashes Severely Elevated Triglycerides in Early Trial

Findings support further studies of potential one-time treatment strategy

two side-by-side medical illustrations with red trend line overlays

Lipoprotein(a) Reduction With Pelacarsen Has No Impact on Cardiac Events, Lp(a)HORIZON Finds

But unexpected results are ‘not the end of the story’ for Lp(a) lowering, investigators say

stylized heart and lungs with text overlay

Outcome Updates in Adult Cardiac Surgery, Ischemic Heart Disease and Vascular Disease

A scannable snapshot of recent volumes and results

illustration of aortic arch after stent graft repair

Evolving Strategies in Aortic Arch Repair (Podcast)

Earlier detection is reshaping timing and safety of these increasingly common surgeries

illustrated human gut with microbes and an overlay of a rhythm tracing

TMAO Shown to Be a Modifiable Risk Factor for Atrial Fibrillation

Bench-to-bedside study identifies mechanism and potential therapeutic target

Ad